Premium
A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients
Author(s) -
TEITEL J.,
BERNTORP E.,
DOLAN G.,
FISCHER K.,
GRINGERI A.,
KESSLER C.,
LAMBERT T.,
LEISSINGER C.,
NEMES L.,
SHIMA M.
Publication year - 2011
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2010.02440.x
Subject(s) - medicine , haemophilia , clinical trial , statement (logic) , standardization , haemophilia a , alternative medicine , medline , intensive care medicine , family medicine , pediatrics , pathology , political science , law
Summary. The haemophilia literature increasingly contains reports describing the use of bypassing agent prophylaxis (BAP) in patients with severe haemophilia A and inhibitors. However, it is difficult to interpret and compare the results and draw conclusions about treatment efficacy because of small patient numbers and a lack of standardization among BAP studies. This article presents consensus recommendations for standardizing future BAP clinical trials developed by an international panel of haemophilia opinion leaders.